Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at biotech/
Analysts Hunt for Undervalued Biotech Stocks
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at biotech/biopharma
Express News | EF Hutton Initiates Coverage On Citius Pharma With Buy Rating, Announces Price Target of $6
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Are Analysts Optimistic?
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Citius Pharmaceuticals, Inc., a late-
Biopharma Stocks Transformative Innovation for the Future of Health
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at transformative
Express News | Citius Pharmaceuticals Announced Expected Milestones in H2 2024
Express News | Citius Pharmaceuticals: Preparing for Near-Term Commercialization of Lymphir IF Approved
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Sidoti Events, LLC's Virtual June Small-Cap Conference
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Conference taking place
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $4 price target.
Citius Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 497.82% HC Wainwright & Co. $4 → $4 Reiterates Buy → Buy 02/14/2024 497.82% HC Wainwright & Co.
Buy Rating Reaffirmed for Citius Pharmaceuticals Amid Strong Clinical Trial Results and Growth Prospects
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Analysts Are Bullish on Top Healthcare Stocks: Citius Pharmaceuticals (CTXR), Actinium Pharmaceuticals (ATNM)
Citius Pharma's 'Antibiotic Lock' Effective In Patients With Catheter-Associated Bloodstream Infections
Tuesday, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) announced the topline results of its Phase 3 trial of Mino-Lok, an antibiotic lock solution designed to salvage catheters in patients with central li
Express News | Citius Pharmaceuticals Shares up 10.5% After Co's Anti-Infective Drug Succeeds in Late-Stage Study
Citius Gains as Late-stage Trial for Mino-Lok Succeeds
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 67.7% to $2.13 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.3 million. Durect (NASDAQ:DRR
Express News | Citius Pharmaceuticals Shares Are Trading Higher After the Company's Phase 3 Trial of Mino-Lok Met Primary and Secondary Endpoints
Express News | Trading Halt: Halt Status Updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times